- Department of Cardiology, Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, HungaryInterests: Animal physiology; Signaling pathways; Cardiac function; Physiology; Patch-clamp electrophysiology; Electrophysiology; Cell signaling; Signal transduction; Signaling; Phosphorylation
Dear Colleagues,
Indices of myocardial morphology and function should fall within physiological ranges at both the macroscopic and microscopic levels for stable cardiac performance. Accordingly, cardiac chamber sizes together with the characteristics of cardiomyocytes and their subcellular micro-organelles are to be analyzed in combination for the correct interpretation of cardiac health and disease.
Upon various different stress conditions (i.e. hemodynamic pressure- or volume-overload, genetic predispositions, etc.) cardiac muscle enters a transformation process, commonly referred to as cardiac hypertrophy. Thickening of the heart muscle often appears as a compensatory mechanism, nevertheless, concomitant alterations in cardiomyocyte signaling can also limit systolic and/or diastolic functions and evoke life-threatening arrhythmias. In this context, concentric left ventricular hypertrophy has been mostly associated with diastolic dysfunction, leading potentially to heart failure with preserved ejection fraction (HFpEF), while heart failure with reduced ejection fraction (HfrEF) is more often seen in conditions with left ventricular dilation. Nevertheless, making pathophysiological distinctions between HFpEF, HFrEF and the relatively novel category of heart failure with mid-range ejection fraction (HfmrEF) are not without problems. This is due to the high number of overlapping comorbidities and risk factors (e.g. hypertension, atherosclerosis, metabolic derangements, infective-immunological factors, etc.) rarely resulting in pure forms of cardiac pathologies.
Our current view on cardiac remodeling links over-activated neuro-humoral pathways (e.g. the renin-angiotensin-aldosterone system and the beta-adrenergic system) to exhaustive levels of cardiomyocyte receptor stimulations, to an aphysiological function of the intracellular signaling cascades, and ultimately to a modified epigenetic control over cardiomyocytes. One of the hurdles of present time cardiology is the difficulty in finding effective medications acting closer to the distal end of the above chain (i.e. cardiomyocyte nuclei) than to the proximal, like current heart failure medications. In this issue, entitled “Cardiac Hypertrophy: from Basic Science to Clinical Application” we present recent advances in the field of cardiac remodeling and its management to foster preclinical and clinical efforts for the preservation of cardiac integrity and function.
Prof. Dr. Zoltán Papp and Dr. Attila Kiss
Guest Editors
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.
- Open Access ReviewCardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure DevelopmentAlfredo Caturano, Erica Vetrano, Raffaele Galiero, Teresa Salvatore, ... Ferdinando Carlo SassoRev. Cardiovasc. Med. 2022, 23(5), 165; https://doi.org/10.31083/j.rcm2305165(This article belongs to the Special Issue Cardiac Hypertrophy: from Basic Science to Clinical Application)283Downloads3Citations840Views
- Open Access Systematic ReviewThe Effect of Angiotensin II Receptor Blockers in Patients with Hypertrophic Cardiomyopathy: An Updated Systematic Review and Meta-analysis of Randomized Controlled TrialsBasel Abdelazeem, Kirellos Said Abbas, Soban Ahmad, Hasan Raslan, ... Pramod SavarapuRev. Cardiovasc. Med. 2022, 23(4), 141; https://doi.org/10.31083/j.rcm2304141(This article belongs to the Special Issue Cardiac Hypertrophy: from Basic Science to Clinical Application)92Downloads2Citations379Views
- Open Access Original ResearchIncrease of Oxidative Stress by Deficiency of The ALDH2/UCP2/Nrf2 Axis Exacerbates Cardiac Dysfunction in Chronic Kidney DiseaseLei Xu, Shasha Han, Zhaoyang Chen, Cheng Shen, ... Junbo GeRev. Cardiovasc. Med. 2022, 23(4), 127; https://doi.org/10.31083/j.rcm2304127(This article belongs to the Special Issue Cardiac Hypertrophy: from Basic Science to Clinical Application)46Downloads1Citations238Views